Vertex Pharmaceuticals Incorporated (VX1.DE)

EUR 446.45

(-0.18%)

Long Term Debt Summary of Vertex Pharmaceuticals Incorporated

  • Vertex Pharmaceuticals Incorporated's latest annual long term debt in 2023 was 724.7 Million USD , up 53.67% from previous year.
  • Vertex Pharmaceuticals Incorporated's latest quarterly long term debt in 2024 Q2 was 933.4 Million USD , down 0.0% from previous quarter.
  • Vertex Pharmaceuticals Incorporated reported annual long term debt of 471.6 Million USD in 2022, down -15.29% from previous year.
  • Vertex Pharmaceuticals Incorporated reported annual long term debt of 556.7 Million USD in 2021, down -4.26% from previous year.
  • Vertex Pharmaceuticals Incorporated reported quarterly long term debt of 721.3 Million USD for 2024 Q1, down 0.0% from previous quarter.
  • Vertex Pharmaceuticals Incorporated reported quarterly long term debt of 724.7 Million USD for 2023 Q4, down -2.69% from previous quarter.

Annual Long Term Debt Chart of Vertex Pharmaceuticals Incorporated (2023 - 1990)

Historical Annual Long Term Debt of Vertex Pharmaceuticals Incorporated (2023 - 1990)

Year Long Term Debt Long Term Debt Growth
2023 724.7 Million USD 53.67%
2022 471.6 Million USD -15.29%
2021 556.7 Million USD -4.26%
2020 581.47 Million USD 0.71%
2019 577.37 Million USD 1.8%
2018 567.16 Million USD 0.58%
2017 563.91 Million USD -32.73%
2016 838.24 Million USD 2.15%
2015 820.61 Million USD -0.57%
2014 825.29 Million USD 87.17%
2013 440.93 Million USD -34.45%
2012 672.63 Million USD 68.16%
2011 400 Million USD 0.0%
2010 400 Million USD 160.02%
2009 153.83 Million USD -46.49%
2008 287.5 Million USD 0.0%
2007 - USD -100.0%
2006 19.99 Million USD -88.9%
2005 180.09 Million USD -46.24%
2004 334.99 Million USD -1.68%
2003 340.72 Million USD 4.54%
2002 325.94 Million USD 0.9%
2001 323.02 Million USD -6.99%
2000 347.31 Million USD 7289.64%
1999 4.7 Million USD -32.86%
1998 7 Million USD 18.64%
1997 5.9 Million USD 5.36%
1996 5.6 Million USD 14.29%
1995 4.9 Million USD 4.26%
1994 4.7 Million USD 11.9%
1993 4.2 Million USD 27.27%
1992 3.3 Million USD 57.14%
1991 2.1 Million USD -12.5%
1990 2.4 Million USD 0.0%

Peer Long Term Debt Comparison of Vertex Pharmaceuticals Incorporated

Name Long Term Debt Long Term Debt Difference
BioNTech SE 191 Million EUR -279.424%
CureVac N.V. 36.81 Million EUR -1868.277%
Biotest Aktiengesellschaft 377.3 Million EUR -92.075%
Biotest Aktiengesellschaft 377.3 Million EUR -92.075%
BRAIN Biotech AG 25.19 Million EUR -2776.593%
Formycon AG 7.81 Million EUR -9173.193%
Heidelberg Pharma AG 70.4 Thousand EUR -1029201.064%
Medigene AG 2.03 Million EUR -35494.303%